Literature DB >> 1457662

Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review.

J Bisbe1, J M Miro, X Latorre, A Moreno, J Mallolas, J M Gatell, J P de la Bellacasa, E Soriano.   

Abstract

From November 1983 to April 1990, disseminated candidiasis was diagnosed in 83 heroin addicts at our institution. All patients had consumed brown heroin diluted in fresh lemon juice. Sixty-two (75%) had skin lesions, 41 (49%) had ocular lesions, and 35 (42%) had one or several costochondral tumors. Candida albicans was grown in culture or histopathologically identified in 34 cases (41%). The patients who had only cutaneous lesions were treated with ketoconazole, and they were all cured. The patients with ocular involvement received systemic amphotericin B with or without oral flucytosine; 29 of these patients developed varying degrees of vision loss. The method of treatment of costochondral tumors was not uniform; in 14 cases the lesions were resected. The one patient who died developed endocarditis involving the aortic valve. Cases of pleuropulmonary involvement, spondylitis, and large-joint arthritis have also been described among the 300 cases reported in the reviewed literature. This is a new syndrome of candidal infection in drug addicts who use brown heroin; ocular lesions are the most harmful manifestation, and loss of vision is the major sequela.

Entities:  

Mesh:

Year:  1992        PMID: 1457662     DOI: 10.1093/clind/15.6.910

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Emerging and Underrecognized Complications of Illicit Drug Use.

Authors:  Alysse G Wurcel; Elisabeth A Merchant; Roger P Clark; David R Stone
Journal:  Clin Infect Dis       Date:  2015-08-12       Impact factor: 9.079

2.  Fungal endocarditis.

Authors:  George M Varghese; Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2008-07       Impact factor: 3.725

3.  Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient.

Authors:  J Berenguer; T M Diaz-Guerra; B Ruiz-Diez; J C Bernaldo de Quiros; J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

4.  Fire in the vein: Heroin acidity and its proximal effect on users' health.

Authors:  Daniel Ciccarone; Magdalena Harris
Journal:  Int J Drug Policy       Date:  2015-04-17

Review 5.  Infective endocarditis in intravenous drug abusers: an update.

Authors:  C Sousa; C Botelho; D Rodrigues; J Azeredo; R Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-20       Impact factor: 3.267

6.  Endogenous endophthalmitis in patients with intravenous opioid use: demographics and associated comorbidities.

Authors:  Aditya Uppuluri; Marco A Zarbin; Neelakshi Bhagat
Journal:  Int Ophthalmol       Date:  2021-01-27       Impact factor: 2.031

7.  Gluconobacter as well as Asaia species, newly emerging opportunistic human pathogens among acetic acid bacteria.

Authors:  Corentine Alauzet; Corinne Teyssier; Estelle Jumas-Bilak; Anne Gouby; Raphael Chiron; Christian Rabaud; François Counil; Alain Lozniewski; Hélène Marchandin
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

8.  Candida endophthalmitis: A critical diagnosis in the critically ill.

Authors:  L Au; K Guduru; G Lipscomb; S P Kelly
Journal:  Clin Ophthalmol       Date:  2007-12

9.  Injection Drug Use-Associated Candidemia: Incidence, Clinical Features, and Outcomes, East Tennessee, 2014-2018.

Authors:  John A Rossow; Radhika Gharpure; Julia Brennan; Pryanka Relan; Sabrina R Williams; Snigdha Vallabhaneni; Brendan R Jackson; Caroline R Graber; Sherry R Hillis; William Schaffner; John R Dunn; Timothy F Jones
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

10.  Chronic Meningitis: Simplifying a Diagnostic Challenge.

Authors:  Kelly Baldwin; Chris Whiting
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 6.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.